2012•Current Rheumatology ReportsOpen access
The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus
Anne Davidson
Open full text 48 citations
Abstract
This record does not include an abstract. Use the full-text link above if available.
Anne Davidson
Abstract
An abstract is not available in the OpenAlex record for this paper.
OpenAlex reports 48 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Key concepts: B-cell activating factor, Belimumab, Medicine, Systemic lupus erythematosus, Immunology, Clinical trial, Rheumatology, Internal medicine